Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival

Table 3 Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

Factor	HR	CI 95%	P
T-status			<0.001 ^†
T1	1.00
T2	1.60	(0.97-2.64)	0.065
T3	3.80	(2.13-6.77)	<0.001
N-status			<0.001 ^†
N0	1.00
N1	2.01	(1.30-3.11)	0.002
N2	3.08	(1.74-5.44)	<0.001
Differentiation			0.009 ^†
Well	1.00
Moderate	1.17	(0.63-2.20)	0.618
Poor	2.08	(1.12-3.85)	0.020
Performance status			0.040 ^†
ECOG 0	1.00
ECOG 1	1.52	(1.02-2.26)	0.040
ECOG 2	2.15	(0.94-4.91)	0.069
Vascular infiltration
No	1.00
Yes	1.70	(1.01-2.87)	0.046
Histology			<0.001 ^†
Squamous carcinoma	1.00
Adenocarcinoma	2.23	(1.48-3.35)	<0.001
Large cell carcinoma	0.80	(0.39-1.66)	0.555
CXC16 stromal cells
Low	1
High	0.55	(0.35-0.87)	0.011
CXCL16 cancer and stromal cells*			0.031 ^†
Low/Low	1.00
Low/High + High/Low	0.57	(0.35-0.93)	0.023
High/High	0.42	(0.20-0.88)	0.022

^†Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p < 0.05

ISSN: 1471-2407